206 related articles for article (PubMed ID: 32460795)
1. Discrimination between clinical significant and insignificant prostate cancer with apparent diffusion coefficient - a systematic review and meta analysis.
Meyer HJ; Wienke A; Surov A
BMC Cancer; 2020 May; 20(1):482. PubMed ID: 32460795
[TBL] [Abstract][Full Text] [Related]
2. Correlations between Apparent Diffusion Coefficient and Gleason Score in Prostate Cancer: A Systematic Review.
Surov A; Meyer HJ; Wienke A
Eur Urol Oncol; 2020 Aug; 3(4):489-497. PubMed ID: 31412009
[TBL] [Abstract][Full Text] [Related]
3. Can dynamic contrast enhanced MRI predict gleason score in prostate cancer? a systematic review and meta analysis.
Meyer HJ; Wienke A; Surov A
Urol Oncol; 2021 Nov; 39(11):784.e17-784.e25. PubMed ID: 33934966
[TBL] [Abstract][Full Text] [Related]
4. Quantitative evaluation of the relative apparent diffusion coefficient values on multiparametric magnetic resonance imaging to predict higher Gleason score prostate cancer.
Kato S; Kamijima S; Inaoka T; Kamiya N; Sasai D; Terada H; Hiruta N; Suzuki H
Scand J Urol; 2018 Jun; 52(3):180-185. PubMed ID: 29939084
[TBL] [Abstract][Full Text] [Related]
5. Apparent diffusion coefficient values are superior to transrectal ultrasound-guided prostate biopsy for the assessment of prostate cancer aggressiveness.
Li C; Chen M; Wang J; Wang X; Zhang W; Zhang C
Acta Radiol; 2017 Feb; 58(2):232-239. PubMed ID: 27055916
[TBL] [Abstract][Full Text] [Related]
6. Prospective Inclusion of Apparent Diffusion Coefficients in Multiparametric Prostate MRI Structured Reports: Discrimination of Clinically Insignificant and Significant Cancers.
Costa DN; Xi Y; Aziz M; Passoni N; Shakir N; Goldberg K; Francis F; Roehrborn CG; Leon AD; Pedrosa I
AJR Am J Roentgenol; 2019 Jan; 212(1):109-116. PubMed ID: 30383404
[TBL] [Abstract][Full Text] [Related]
7. Incremental value of high b value diffusion-weighted magnetic resonance imaging at 3-T for prediction of extracapsular extension in patients with prostate cancer: preliminary experience.
Kido A; Tamada T; Sone T; Kanomata N; Miyaji Y; Yamamoto A; Ito K
Radiol Med; 2017 Mar; 122(3):228-238. PubMed ID: 27943099
[TBL] [Abstract][Full Text] [Related]
8. Clinically insignificant prostate cancer suitable for active surveillance according to Prostate Cancer Research International: Active surveillance criteria: Utility of PI-RADS v2.
Yim JH; Kim CK; Kim JH
J Magn Reson Imaging; 2018 Apr; 47(4):1072-1079. PubMed ID: 28901655
[TBL] [Abstract][Full Text] [Related]
9. Apparent Diffusion Coefficient (ADC) Ratio Versus Conventional ADC for Detecting Clinically Significant Prostate Cancer With 3-T MRI.
Bajgiran AM; Mirak SA; Sung K; Sisk AE; Reiter RE; Raman SS
AJR Am J Roentgenol; 2019 Sep; 213(3):W134-W142. PubMed ID: 31216201
[No Abstract] [Full Text] [Related]
10. Apparent diffusion coefficient value and ratio as noninvasive potential biomarkers to predict prostate cancer grading: comparison with prostate biopsy and radical prostatectomy specimen.
De Cobelli F; Ravelli S; Esposito A; Giganti F; Gallina A; Montorsi F; Del Maschio A
AJR Am J Roentgenol; 2015 Mar; 204(3):550-7. PubMed ID: 25714284
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Diffusion Kurtosis Imaging Versus Standard Diffusion Imaging for Detection and Grading of Peripheral Zone Prostate Cancer.
Roethke MC; Kuder TA; Kuru TH; Fenchel M; Hadaschik BA; Laun FB; Schlemmer HP; Stieltjes B
Invest Radiol; 2015 Aug; 50(8):483-9. PubMed ID: 25867657
[TBL] [Abstract][Full Text] [Related]
12. The correlation between biological activity and diffusion-weighted MR imaging and ADC value in cases with prostate cancer.
Sokmen BK; Sokmen D; Ucar N; Ozkurt H; Simsek A
Arch Ital Urol Androl; 2017 Dec; 89(4):277-281. PubMed ID: 29473377
[TBL] [Abstract][Full Text] [Related]
13. Discrimination between malignant and benign thyroid tumors by diffusion-weighted imaging - A systematic review and meta analysis.
Meyer HJ; Wienke A; Surov A
Magn Reson Imaging; 2021 Dec; 84():41-57. PubMed ID: 34560233
[TBL] [Abstract][Full Text] [Related]
14. Conventional vs. reduced field of view diffusion weighted imaging of the prostate: Comparison of image quality, correlation with histology, and inter-reader agreement.
Warndahl BA; Borisch EA; Kawashima A; Riederer SJ; Froemming AT
Magn Reson Imaging; 2018 Apr; 47():67-76. PubMed ID: 29103977
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Diffusion-weighted MR Images Based on a Gamma Distribution Model to Differentiate Prostate Cancers with Different Gleason Score.
Tomita H; Soga S; Suyama Y; Ito K; Asano T; Shinmoto H
Magn Reson Med Sci; 2020 Feb; 19(1):40-47. PubMed ID: 30918223
[TBL] [Abstract][Full Text] [Related]
16. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy.
Woodfield CA; Tung GA; Grand DJ; Pezzullo JA; Machan JT; Renzulli JF
AJR Am J Roentgenol; 2010 Apr; 194(4):W316-22. PubMed ID: 20308476
[TBL] [Abstract][Full Text] [Related]
17. Prostate Cancer: Diffusion-weighted MR Imaging for Detection and Assessment of Aggressiveness-Comparison between Conventional and Kurtosis Models.
Tamada T; Prabhu V; Li J; Babb JS; Taneja SS; Rosenkrantz AB
Radiology; 2017 Jul; 284(1):100-108. PubMed ID: 28394755
[TBL] [Abstract][Full Text] [Related]
18. [Utility of diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient in detection of prostate cancer and prediction of pathologic Gleason score].
Kagebayashi Y; Nakai Y; Matsumoto Y; Samma S; Miyasaka T; Nakagawa H
Hinyokika Kiyo; 2012 Aug; 58(8):405-8. PubMed ID: 23052263
[TBL] [Abstract][Full Text] [Related]
19. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer aggressive prediction: preponderant diagnostic performances of intravoxel incoherent motion (IVIM) imaging and diffusion kurtosis imaging (DKI) beyond ADC at 3.0 T scanner with gleason score at final pathology.
Shan Y; Chen X; Liu K; Zeng M; Zhou J
Abdom Radiol (NY); 2019 Oct; 44(10):3441-3452. PubMed ID: 31144091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
